off-label use of glp-1 agonists for obesity in 2016 Chart: 1 8 Americans Now Drugs Weight Loss Mapping the effectiveness and risks

Abdominal fat loss, as well as sustained reductions of fasting insulin levels and markers of IR, have been also shown to individuals with overweight/obesity, prediabetes, PCOS and OSA during their administration [31, 38, 6770]

IV may be more suitable for those focused on cellular revitalization and long-term longevity

9 (8): p

GLP-1 Medications: Work with natural hunger hormones Multiple complementary mechanisms Target biological causes of overeating Produce 10-22% average weight loss Much more effective than traditional options Medical Uses: FDA-Approved Indications: For Type 2 Diabetes: All GLP-1 medications originally approved for diabetes Improve blood sugar control Reduce A1C by 1-2 percentage points Lower risk of cardiovascular events For Chronic Weight Management: Semaglutide (Wegovy): Approved 2021 Tirzepatide (Zepbound): Approved 2023 Liraglutide (Saxenda): Approved 2014 Requirements for weight loss approval: BMI 30, or BMI 27 with weight-related condition (diabetes, hypertension, sleep apnea, etc.) Off-Label Use: Many doctors prescribe diabetes versions (Ozempic, Mounjaro) off-label for weight loss because: Identical medication to weight loss versions Sometimes better insurance coverage Same effectiveness regardless of indication on label This is legal and common medical practice